(EXAS) - Analyzing Exact Sciences's Short Interest
AbbVie's Options: A Look at What the Big Money Is Thinking
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Viking Therapeutics Analyst Ratings
Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024
Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling...
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer
Obesity Drug Coverage Could Boost Spending By $35B Through 2034
Viking Therapeutics Unusual Options Activity
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
AbbVie Analyst Ratings
Gilead Upgraded to Overweight by Wells Fargo, PrEP Launch Cited
U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To...
Liquidia Jumps as Court Rejects United Therapeutics Request for Appeal in Patent Dispute
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights